Healthcare
China Traditional Chinese Medicine Holdings Co. Ltd.(CHIZF)
Live Price
Offline$0.219
+0.00% today
1Y Change
-8.73%
Window
Jun 25, 2025 → Jun 18, 2026
- Market Cap
- $7.55B
- Revenue Growth
- -13.0%
- EPS Growth
- -720.6%
- Dividend Yield
- 5.0%
Coverage: 253 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
China Traditional Chinese Medicine Holdings Co. Ltd. (CHIZF) is a Healthcare stock with a market cap of $7.55B and listed on OTC. The stock last traded around $0.22 and down 8.7% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -13.0%, EPS growth of -720.6%, a dividend yield of 5.0%. What stands out right now is revenue -13.0%, EPS -720.6%, free cash flow -5.5% with operating margin 1.0% and ROIC 0.5%. The dividend matters to the case here, with a current yield around 5.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CHIZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-13.0% vs +7.6% peer median
Operating Margin
Below sector median
+1.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -13.0% and EPS is at -720.6%, with operating margin around 1.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 5.0%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
CHIZF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CHIZF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CHIZF Max Drawdown
-36.61%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CHIZF and SPY.
Company Overview
China Traditional Chinese Medicine Holdings Co. Ltd.
OTC
China Traditional Chinese Medicine Holdings Co. Ltd. is a leading pharmaceutical company specializing in the manufacture and sale of traditional Chinese medicine products. Serving as the core platform for traditional Chinese medicine under the Sinopharm Group, the company plays a crucial role in modernizing and commercializing centuries-old herbal treatment methods for contemporary healthcare needs. Its business encompasses the development, production, and distribution of a diverse range of TCM products, including herbal extracts, proprietary Chinese medicines, and related healthcare goods. Ranked among the top Chinese national medicine brands, China Traditional Chinese Medicine Holdings is significant for its large-scale operations and integration within China’s broader pharmaceutical landscape. The company supports public health by making traditional remedies more widely accessible, bridging historical practices with modern healthcare systems, and influencing both domestic and international TCM markets.
- Employees
- 14.8k
- Street Address
- Emperor Group Centre, Room 1601 288 Hennessy Road
- Mailing
- Wan Chai
- Region
- Wan Chai, Hong Kong
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 4.1
- Price/Sales
- 0.5
- Price/Book
- 0.4
Growth
- Revenue
- -13.0%
- EPS
- -720.6%
- Free Cash Flow
- -5.5%
Profitability
- Gross Margin
- 48.1%
- Operating Margin
- 1.0%
- Net Margin
- -2.3%
- ROE
- -1.6%
- ROIC
- 0.5%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 2.29
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.